Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | USL311 |
Synonyms | |
Therapy Description |
USL311 is a CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may inhibit proliferation and migration of tumor cells expressing CXCR4 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
USL311 | USL-311|USL 311 | CXCR4 Inhibitor 15 | USL311 is a CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may inhibit proliferation and migration of tumor cells expressing CXCR4 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02765165 | Phase Ib/II | Lomustine + USL311 USL311 | Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) | Terminated | USA | ESP | 0 |